Hammersmith Medicines Research is an early phase research unit offering full service support for Phase 1 and 2a studies. We work over a wide range of therapeutic areas and IMP types (small molecule, biological and vaccines). We regularly undertake studies with various psychedelics in both healthy participants and different patient populations.

The PsychedeliCare Initiative is the first European Citizens' Initiative dedicated to raise awareness about the benefits of psychedelic-assisted therapies (PATs) for mental health in the EU. Through a year-long European campaign, the initiative aims to collect one million signatures to formally call on the European Commission to ensure equitable, timely, affordable, safe, and legal access to PATs in the EU.

Bridging the gap between fungal wisdom and modern understandings of wellness, our service allows you to incorporate functional mushrooms and natural remedies into your life in the way that works best for you. Whether you're new to functional mushrooms or looking to enhance your health routine, a personalised one-on-one consultation will provide tailored advice to suit your specific needs.

Shortwave Life Sciences is a biopharmaceutical company developing novel drug combinations and delivery methods to treat patients suffering from life-threatening mental health disorders. We identify, operate and create value from early-stage, breakthrough initiatives, with an initial focus on eating disorders and anorexia nervosa.

The Imperial Centre for Psychedelic Research and the CIPPRes Clinic are leading psychedelic research in the United Kingdom, building on over a decade of pioneering work in this area carried out at Imperial College London, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.